Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

The company said the patient, an African American-Asian woman diagnosed with lupus nephritis, received fludarabine-free ...

Aurinia Pharmaceuticals (AUPH) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall ...

Fate Therapeutics (NASDAQ:FATE) stock closed 12% higher Monday after soaring as much as 73% on news that the first patient in ...

There are multiple chapters near you. Select your preferred chapter.

One of the key drivers behind the stock’s impressive jump is the recent presentation of initial clinical and translational data from the company’s ongoing FT819 Phase 1 Autoimmunity study at the ...

Lupus nephritis (LN) diagnosis could improve greatly if early results with a multimarker urine test are confirmed in larger ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) commends the American College of Rheumatology (ACR) for their 2024 evidence-based guidelines for the screening, treatment, and ...

When data from two data sources were analyzed -- one of commercial health insurance claims, the other from Medicare -- ...

Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals has unveiled new data underscoring the importance of early ...

Then there’s physical activity: Many of the symptoms of lupus, such as joint pain, fatigue, and depression, may make patients ...